Blurbs

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), CM Life Sciences III (EQRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sanofi (SNYNFResearch Report), CM Life Sciences III (EQRXResearch Report) and Ventyx Biosciences (VTYXResearch Report) with bullish sentiments.

Sanofi (SNYNF)

UBS analyst Laura Sutcliffe maintained a Buy rating on Sanofi yesterday and set a price target of EUR122.00. The company’s shares closed last Wednesday at $99.66.

Sutcliffe has an average return of 4.7% when recommending Sanofi.

According to TipRanks.com, Sutcliffe is ranked #3195 out of 7923 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $117.56 average price target, representing a 17.3% upside. In a report issued on March 14, J.P. Morgan also maintained a Buy rating on the stock with a EUR105.00 price target.

See the top stocks recommended by analysts >>

CM Life Sciences III (EQRX)

Jefferies analyst Akash Tewari maintained a Buy rating on CM Life Sciences III yesterday and set a price target of $5.60. The company’s shares closed last Wednesday at $3.90.

According to TipRanks.com, Tewari is a 5-star analyst with an average return of 30.4% and a 65.1% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Madrigal Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CM Life Sciences III with a $5.60 average price target.

Ventyx Biosciences (VTYX)

In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Ventyx Biosciences, with a price target of $30.00. The company’s shares closed last Wednesday at $11.21, close to its 52-week low of $9.50.

According to TipRanks.com, Yee ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -2.8% and a 40.4% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Denali Therapeutics, and Aligos Therapeutics.

Currently, the analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $40.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SNYNF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More